Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer

White Plains Hospital is the first U.S. site
to offer this innovative treatment to cancer patients